Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term.

Chen L, Li G, Li J, Fan C, Xu J, Wu B, Liu K, Zhang C.

Cancer Chemother Pharmacol. 2013 Apr;71(4):921-8. doi: 10.1007/s00280-013-2083-3. Epub 2013 Jan 25.

PMID:
23355039
2.

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B.

Br J Cancer. 2008 Apr 22;98(8):1398-402. doi: 10.1038/sj.bjc.6604317. Epub 2008 Mar 25.

3.

[Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].

Huang J, Hu H, Xie Y, Tang Y, Liu W, Zhong M.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Jun;38(6):582-9. doi: 10.3969/j.issn.1672-7347.2013.06.006. Chinese.

4.

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2008 Dec;33(6):1257-62.

PMID:
19020759
5.

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L.

J Clin Oncol. 1998 Jan;16(1):309-16.

PMID:
9440758
7.

Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.

Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK.

Cancer. 2013 Sep 1;119(17):3242-50. doi: 10.1002/cncr.28175. Epub 2013 May 29.

8.
9.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
10.

Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.

Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.

Anticancer Res. 2011 Nov;31(11):3843-9.

PMID:
22110208
11.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.

PMID:
20504223
12.

Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.

Monica V, Familiari U, Chiusa L, Rossi G, Novero D, Busso S, Ruffini E, Ardissone F, Scagliotti GV, Papotti M.

Lung Cancer. 2013 Mar;79(3):228-35. doi: 10.1016/j.lungcan.2012.12.003. Epub 2012 Dec 28.

PMID:
23276504
13.

Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.

Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G.

Anticancer Res. 2002 Sep-Oct;22(5):2805-9.

PMID:
12530000
14.

Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.

Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M.

Anticancer Res. 1999 Nov-Dec;19(6C):5635-40.

PMID:
10697632
15.

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.

Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y.

BMC Gastroenterol. 2012 Sep 29;12:137. doi: 10.1186/1471-230X-12-137. Review.

16.

Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.

Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ.

Biomarkers. 2011 Feb;16(1):74-82. doi: 10.3109/1354750X.2010.533284. Epub 2010 Dec 6.

PMID:
21133646
17.

Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.

Ishido K, Azuma M, Koizumi W, Takeuchi A, Sakuramoto S, Watanabe M, Okayasu I.

Pharmacogenet Genomics. 2009 Dec;19(12):955-64. doi: 10.1097/FPC.0b013e328333351b.

PMID:
19898266
18.

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.

Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.

Cancer Chemother Pharmacol. 2012 May;69(5):1277-87. doi: 10.1007/s00280-012-1834-x.

PMID:
22302408
19.

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr.

Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

20.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866

Supplemental Content

Support Center